162 related articles for article (PubMed ID: 31901479)
21. Adverse prognostic impact of bone marrow microvessel density in multiple myeloma.
Lee N; Lee H; Moon SY; Sohn JY; Hwang SM; Yoon OJ; Youn HS; Eom HS; Kong SY
Ann Lab Med; 2015 Nov; 35(6):563-9. PubMed ID: 26354343
[TBL] [Abstract][Full Text] [Related]
22. Multiple myeloma international staging system: "staging" or simply "aging" system?
Bataille R; Annweiler C; Beauchet O
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):635-7. PubMed ID: 24035714
[TBL] [Abstract][Full Text] [Related]
23. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
24. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
Foulk B; Schaffer M; Gross S; Rao C; Smirnov D; Connelly MC; Chaturvedi S; Reddy M; Brittingham G; Mata M; Repollet M; Rojas C; Auclair D; DeRome M; ; Weiss B; Sasser AK
Br J Haematol; 2018 Jan; 180(1):71-81. PubMed ID: 29105742
[TBL] [Abstract][Full Text] [Related]
25. Metabolic markers for diagnosis and risk-prediction of multiple myeloma.
Fei F; Ma T; Zhou X; Zheng M; Cao B; Li J
Life Sci; 2021 Jan; 265():118852. PubMed ID: 33278388
[TBL] [Abstract][Full Text] [Related]
26. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic implications of myeloma staging.
Durie BG; Bataille R
Eur J Haematol Suppl; 1989; 51():111-6. PubMed ID: 2697583
[TBL] [Abstract][Full Text] [Related]
28. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
29. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
30. [A case of Bence-Jones protein-lambda positive multiple myeloma complicated by abnormal plasma cells in pleural effusion].
Shirai T; Hashizume I; Kasamatsu N; Nakamura A; Yamatani H; Hanzawa S; Momiki S; Sasaki K; Yano K; Ozawa T
Nihon Kokyuki Gakkai Zasshi; 1998 Feb; 36(2):176-81. PubMed ID: 9617146
[TBL] [Abstract][Full Text] [Related]
31. New blood markers detection technology: A leap in the diagnosis of gastric cancer.
Beeharry MK; Liu WT; Yan M; Zhu ZG
World J Gastroenterol; 2016 Jan; 22(3):1202-12. PubMed ID: 26811658
[TBL] [Abstract][Full Text] [Related]
32. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies.
Davidson B
Virchows Arch; 2018 Oct; 473(4):395-403. PubMed ID: 30145616
[TBL] [Abstract][Full Text] [Related]
34. Myeloma genetics and genomics: practice implications and future directions.
Faiman B
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.
Alexandrakis MG; Neonakis IK; Pappa CA; Konsolas I; Kokonozaki M; Vyzoukaki R; Soundoulounaki S; Xekalou A; Sfiridaki K; Tsirakis G
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1503-9. PubMed ID: 25773125
[TBL] [Abstract][Full Text] [Related]
36. N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.
Chen J; Fang M; Chen X; Yi C; Ji J; Cheng C; Wang M; Gu X; Sun Q; Gao C
BMC Cancer; 2017 Dec; 17(1):881. PubMed ID: 29268706
[TBL] [Abstract][Full Text] [Related]
37. [Prognositic factors in multiple myeloma].
Nagura E
Nihon Rinsho; 2007 Dec; 65(12):2351-6. PubMed ID: 18069282
[TBL] [Abstract][Full Text] [Related]
38. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
39. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review.
Cosemans C; Oben B; Arijs I; Daniëls A; Declercq J; Vanhees K; Froyen G; Maes B; Mebis J; Rummens JL
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):235-248. PubMed ID: 29506935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
